Search research articles
Contact Us
Filters
Showing results (71-80 of 87) with videos related to
Page
of 9
Sort By:
Blood
|
May 6, 2006
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
Ayalew Tefferi, Giovanni Barosi, Ruben A Mesa, et al.
Cancer Medicine
|
June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
Barbara Mora, Elisa Rumi, Paola Guglielmelli, et al.
British Journal of Haematology
|
March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Ejhaem
|
August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severity
Barbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Haematologica
|
January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood
|
May 28, 2005
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Amy V Jones, Sebastian Kreil, Katerina Zoi, et al.
Blood
|
March 6, 2002
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
Moshe Talpaz, Richard T Silver, Brian J Druker, et al.
BMC Cancer
|
April 4, 2018
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia
Ehab Atallah, Charles A Schiffer, Kevin P Weinfurt, et al.
Haematologica
|
September 17, 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
The New England Journal of Medicine
|
March 2, 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 87) with videos related to
Sort By:
Page
of 9
Blood
|
May 6, 2006
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
Ayalew Tefferi, Giovanni Barosi, Ruben A Mesa, et al.
Cancer Medicine
|
June 8, 2019
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
Barbara Mora, Elisa Rumi, Paola Guglielmelli, et al.
British Journal of Haematology
|
March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Ejhaem
|
August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severity
Barbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Haematologica
|
January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood
|
May 28, 2005
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Amy V Jones, Sebastian Kreil, Katerina Zoi, et al.
Blood
|
March 6, 2002
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
Moshe Talpaz, Richard T Silver, Brian J Druker, et al.
BMC Cancer
|
April 4, 2018
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia
Ehab Atallah, Charles A Schiffer, Kevin P Weinfurt, et al.
Haematologica
|
September 17, 2013
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
The New England Journal of Medicine
|
March 2, 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Page
of 9